High flyers are emerging here: NetraMark, Bechtle, Adesso

Bechtle: Analysts celebrate, shares hesitate

For public authorities and small and medium-sized enterprises, digitalization is still at the top of the to-do list. Enormous productivity gains can be achieved in this area. As an IT system house, Bechtle has been well-positioned for years to benefit from digitalization. Bechtle AG offers comprehensive support in the areas of consulting, hardware, and software, through to long-term managed services, such as cloud services and outsourcing, from 70 locations in the DACH region. This all-round service is well-received by customers and generates steady revenues. In the first half of 2025, Bechtle reported a significant increase in demand, and in August, it even received a large government contract. In recent months, almost all analysts, from UBS to Deutsche Bank to Warburg, have reaffirmed their "Buy" recommendations for Bechtle shares. Most recently, Baader Bank raised its target price to EUR 51. Even though Bechtle is a reliable partner for customers, the stock is not moving forward in the long term – it generated no return over the past year.

Adesso can increase margins again

The returns at Adesso are similarly mixed. The Company, which sees itself primarily as an expert in digital transformation rather than a hardware supplier, has achieved a modest return of around 5% on the stock market over the past year, but the outlook for the next three years is bleak: The share price crashed by more than 50% in the long term. Nevertheless, Adesso is growing: for 2025, the Company is forecasting revenue of EUR 1.35 to 1.45 billion, with EBITDA climbing to EUR 105 to 125 million. This would bring the profit margin back up to between 11 and 13% – in 2024, it was still at 7.6%. This is a sign that the investments in personnel and products made by the Company in recent years are paying off. Analysts are also confident: Warburg Research and Berenberg recommended buying Adesso shares in June 2025.

NetraMark delivers AI for the biotech industry – Technical article confirms success

While many IT system houses primarily target small and medium-sized businesses and public administration, NetraMark focuses its software solution on the biotech sector. NetraMark helps make clinical trials more efficient and faster. It does this by using AI to analyze data and make targeted suggestions for improvement. The potential benefits of such AI solutions for the pharmaceutical industry are enormous.

According to a technical article in Nature Biotechnology from July 2025, drug candidates developed with the help of AI now reach Phase I trials at a rate of 80 to 90% – compared to only 40 to 65% for traditionally discovered active ingredients. The article in Nature Biotechnology also describes how AI can reduce the drug development timeline, which previously took between 10 and 15 years, by several years. The Company Asklepion Pharmaceuticals is already benefiting from NetraMark's solutions and is using the NetraAI software in a Phase III study to identify subgroups that benefit most from the drug being tested. Asklepion CEO Jeff Courtney emphasizes that NetraMark's technology opens up "a promising path to faster, safer, and more effective treatments."

Other pharmaceutical companies and biotech firms also see AI as a key technology. Many large companies, such as Roche and Pfizer, invested in AI years ago and are continuing to expand their commitment. Some other companies are instead relying on external service providers to achieve the efficiency gains necessary to remain competitive. According to market researchers at Modor Intelligence, the market for AI in the pharmaceutical industry could grow from USD 4.35 billion in 2025 to over USD 25 billion by 2030. This corresponds to an annual growth rate of over 40%. While customers of traditional IT consultancies are often considered challenging due to entrenched structures and significant path dependencies, biotech and pharmaceutical companies have always been open to innovation and agile in their approach. A company like NetraMark therefore has less to fear from such "obstacles to progress" within its target group than IT system houses like Bechtle or Adesso.

NetraMark shares – When will the starting gun be fired?

The NetraMark share has been showing strong momentum for around a week and has seen double-digit gains in the short term. Looking ahead to the next three years, the share price is moving sideways. It appears that the market has not yet recognized NetraMark's potential: While analysts praise Bechtle and Adesso shares, even though the digitization of small and medium-sized businesses and public authorities is no longer a new trend, NetraMark shares are flying under the radar. This is all the more surprising given that AI is the major growth area in the biotech industry and NetraMark offers proven benefits to its customers. NetraMark shares are a sleeping giant and deserve a spot on every return-oriented watch list!